Cargando…
Sodium-glucose co-transporter 2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an updated systematic review and meta-analysis
OBJECTIVES: Heart failure with mildly reduced ejection fraction (HFmrEF) or heart failure with preserved ejection fraction (HFpEF) are associated with significant morbidity and mortality, as well as growing health and economic burden. Sodium-glucose co-transporter 2 (SGLT2) inhibitors are very pr...
Autores principales: | Wang, Yintang, Gao, Tong, Meng, Chang, Li, Siyuan, Bi, Lei, Geng, Yu, Zhang, Ping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9798580/ https://www.ncbi.nlm.nih.gov/pubmed/36581880 http://dx.doi.org/10.1186/s40001-022-00945-z |
Ejemplares similares
-
Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction
por: Liang, Bo, et al.
Publicado: (2022) -
Promise of sodium–glucose co‐transporter‐2 inhibitors in heart failure with mildly reduced ejection fraction
por: Shen, Xizi, et al.
Publicado: (2022) -
The Role of Sodium-Glucose Cotransporter-2 Inhibition in Heart Failure with Preserved Ejection Fraction
por: Brust-Sisti, Lindsay, et al.
Publicado: (2022) -
Heart Failure with Preserved Ejection Fraction: a Pharmacotherapeutic Update
por: Vaz-Salvador, Pedro, et al.
Publicado: (2022) -
Breakthroughs in the treatment of heart failure with mildly reduced and preserved ejection fraction
por: Talha, Khawaja M., et al.
Publicado: (2022)